Physician profile
Michele Moritz
NPI 1710492582
$3,087.60
in general payments reported to CMS, 2019-2025
35 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $869 · 2022: $1,160 · 2023: $606 · 2024: $453.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,059.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,059.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $943.60 | 2021-2024 | |
| Lilly USA, LLC | $246.71 | 2021-2024 | Jardiance, Zepbound, Emgality |
| Astrazeneca Pharmaceuticals LP | $211.78 | 2021-2024 | Lokelma, Fasenra |
| Astellas Pharma US INC | $175.61 | 2021-2024 | Veozah |
| Novo Nordisk INC | $149.64 | 2021-2023 | Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $148.58 | 2021-2023 | Jardiance |
| Glaxosmithkline, LLC. | $132.61 | 2021-2024 | Trelegy Ellipta |
| Amgen INC. | $124.68 | 2021-2024 | Repatha, Otezla |
| Abbott Laboratories | $92.02 | 2022-2024 | Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $84.45 | 2021-2023 | Xifaxan, Trulance |
| Novartis Pharmaceuticals Corporation | $70.68 | 2022-2023 | |
| Pfizer INC. | $62.22 | 2021-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $56.74 | 2021 | |
| Harmony Biosciences LLC | $55.28 | 2022 | |
| Eisai INC. | $50.17 | 2021-2024 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $46.75 | 2021-2024 | Eliquis |
| Merck Sharp & Dohme LLC | $46.64 | 2021-2023 | Gardasil 9, Vaxelis, Vaxneuvance |
| Biohaven Pharmaceutical Holding Company LTD. | $45.15 | 2022 | |
| Amarin Pharma, INC. | $32.10 | 2021 | |
| Organon LLC | $25.51 | 2022 | |
| Alkermes, INC. | $24.87 | 2022 | |
| Antares Pharma, INC. | $22.77 | 2022 | |
| Exact Sciences Corporation | $20.54 | 2023 | Cologuard Collection Kit |
| Ironwood Pharmaceuticals, INC | $20.31 | 2021 | |
| Jazz Pharmaceuticals INC. | $19.97 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $19.63 | 2023 | Rexulti |
| Xeris Pharmaceuticals, INC. | $19.11 | 2022 | |
| Azurity Pharmaceuticals, INC. | $18.39 | 2024 | Edarbi |
| Esperion Therapeutics, INC. | $18.24 | 2021 | |
| Sanofi-Aventis U.S. LLC | $18.10 | 2022 | |
| Dexcom, INC. | $17.85 | 2023 | Dexcom G6 Transmitter |
| Corcept Therapeutics | $17.45 | 2022 | |
| Idorsia Pharmaceuticals US INC | $17.27 | 2023 | Quviviq |
| Janssen Pharmaceuticals, INC | $16.96 | 2021 | |
| Hologic Sales and Service, LLC | $15.22 | 2024 | Aptima |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michele Moritz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.